PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 25, 2015
Ubl Named Next PhRMA President and CEO
Author(s)Pharmaceutical Technology Editors
Stephen J. Ubl to succeed John J. Castellani as the next president and chief executive officer of PhRMA.
Advertisement
The board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) on Sept. 25, 2015 named Stephen J. Ubl the next president and chief executive officer of the association. He succeeds John J. Castellani, who will be retiring at the end of the year.
Ubl joins PhRMA after more than 10 years as the president and CEO of the Advanced Medical Technology Association where he worked with patient advocacy organizations, providers, and public and private payers. He was a board member of the National Health Council.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement